SENSEX NIFTY

Trastuzumab

Aug 26, 2016 at 09:13 | Source: CNBC-TV18
The European Medicines Agency (EMA) has accepted to review Mylan and Biocons application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers.
Aug 25, 2016 at 20:46 | Source: PTI
This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe, global pharma major Mylan and Biocon said in a statement today.
Jun 04, 2016 at 15:30 | Source: PTI
Global pharma major Mylan Inc, and Biocon have confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms, incomparison to Roche's branded Herceptin used for treatment of cancer
May 24, 2016 at 10:11 | Source: CNBC-TV18
These market filings have a market opportunity of USD 40 billion. In particular, Japan offers a market potential of USD 150 million for its insulin product Glargine, says Biocon's Chairman and Managing Director.
Apr 26, 2016 at 20:00 | Source: PTI
Biotechnology firm Biocon today said its product portfolio will not be affected by an order of the Delhi High Court that prevented the company from calling its breast cancer medicine Trastuzumab as a biosimilar of Roche's Herceptin.
Apr 05, 2016 at 10:41 | Source: Moneycontrol.com
It believes that Biocon's (and its partner Mylan) four potential product filings each in the US and EU would add credibility to its pipeline and bring market recognition. Emerging market monetisation is under way, but the US and EU opportunities will take at least two years, according to report.
Sep 15, 2015 at 16:45 | Source: PTI
GBR 1302, a bi-specific monoclonal antibody, is an artificial protein that is composed of fragments of two different monoclonal antibodies and consequently binds two different types of antigens.
Feb 07, 2014 at 22:27 | Source: CNBC-TV18
The Delhi High Court (HC) has thrown a wrench into plans of Biocon and Mylan to market a breast cancer drug that goes by the scientific name Trastuzumab.
Feb 04, 2014 at 09:59 | Source: PTI
The company's subsidiary Mylan Pharmaceuticals Pvt Ltd has launched the world's first trastuzumab biosimilar, which will be marketed by Mylan under the brand name Hertraz Herceptin, a company statement said.
Jan 18, 2014 at 16:21 | Source: Reuters
Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc.
Messages on Trastuzumab »

jaywon

New Member

2 Followers

Biocon  

at least a dozen big pharma companies are there in the fray for trastuzumab biosimilar pie so its an open secret that there will be a big dog fight for the market share and the weakest will be edged out so expected profits can become huge losses.

12.43 PM Aug 26th

Willwin

Platinum Member

910 Followers

Biocon  

Authorization Application filed by Mylan N.V. (MYL 2.9%) seeking approval of a biosimilar to Roche`s (OTCQX:RHHBY) Herceptin (trastuzumab). Mylan co-developed the product candidate with Indian biopharma firm Biocon (OTC:BCNQY). http://t.in.com/92Jm

9.18 PM Aug 25th

Wire News

Platinum Member

609 Followers

News Now  

European Medicines Agency (EMA) has accepted for review Mylan's application to market biosimilar Trastuzumab, co-developed with Biocon, that is used to treat certain breast and gastric cancers.

8.46 PM Aug 25th

ramanujam11

Gold Member

24 Followers

Biocon  

Results were good.Unexpectedly better than I anticipated. Biosimilar Trastuzumab (Herceptin, Mylan alliance) commences Phase III trials in India. This seems to be a new drug which I did not know this either. It appears,they have lot more valuable molecule which are yet to be valued. KMS is silent

2.03 PM Apr 27th 2012

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.